How should I manage a patient with a history of asthma who was exposed to ammonia cleaning products and now presents with dyspnea and wheezing unresponsive to albuterol?

Management of Ammonia Inhalation with Refractory Bronchospasm

This patient is experiencing chemical-induced bronchospasm from ammonia inhalation, not a typical asthma exacerbation, and requires immediate addition of ipratropium bromide to albuterol, systemic corticosteroids, and consideration for escalation to epinephrine or intubation if no improvement occurs.

Critical Recognition: This is NOT Standard Asthma

The failure to respond to albuterol is a red flag. Ammonia is a potent alkaline irritant that causes direct mucosal injury, airway edema, and can trigger paradoxical bronchospasm 1. This is fundamentally different from allergic asthma—it's a chemical burn of the airways 2, 3.

Immediate Treatment Algorithm

First-Line Escalation (Within First Hour)

Add ipratropium bromide immediately:

• Adults: 0.5 mg nebulized every 20 minutes for 3 doses, mixed with albuterol 4
• The combination of beta-agonist plus anticholinergic significantly reduces hospitalizations in severe airflow obstruction 4
• This addresses the different mechanism of chemical-induced bronchospasm versus typical asthma

Administer systemic corticosteroids now:

• Prednisone 40-80 mg PO or methylprednisolone IV 4
• Do not delay—early corticosteroid administration reduces hospitalization likelihood 4
• Ammonia causes direct inflammatory injury requiring anti-inflammatory therapy beyond bronchodilation 2

Provide supplemental oxygen:

• Target SpO2 >90% (>95% if pregnant or cardiac disease) 4
• Monitor continuously until clear response occurs

Second-Line Escalation (If No Response After 60-90 Minutes)

Consider nebulized epinephrine:

• This provides both bronchodilation AND vasoconstriction to reduce airway edema from chemical injury 2, 5
• Particularly important in ammonia exposure where mucosal edema is prominent 2

Evaluate for impending respiratory failure:

• Watch for: inability to speak, altered mental status, intercostal retractions, worsening fatigue, PaCO2 ≥42 mmHg 4
• Do not delay intubation once deemed necessary 4

Intravenous magnesium sulfate:

• 2 g over 20 minutes in adults if life-threatening or severe after 1 hour of intensive treatment 4
• Conditional recommendation for refractory cases 4

Continuous Monitoring

Reassess after initial bronchodilator dose and again after 3 doses (60-90 minutes) 4. Response to treatment predicts hospitalization need better than initial severity 4.

Critical Pitfalls in Ammonia Exposure

Paradoxical bronchospasm: Albuterol itself can cause life-threatening paradoxical bronchospasm 1. If wheezing worsens with albuterol, stop it immediately and switch to alternative therapy (epinephrine, ipratropium) 1.

Delayed pulmonary edema: Ammonia inhalation causes noncardiogenic pulmonary edema that may develop rapidly 2. The patient in the case report had "copious foamy secretions" immediately post-intubation and refractory hypoxemia despite FiO2 1.0 and PEEP 12 cmH2O 2. Monitor closely for deterioration.

Metabolic complications: Ammonia exposure can cause metabolic acidosis and acute kidney injury 6. Check basic metabolic panel, particularly if exposure was significant.

This is NOT maintenance asthma therapy: Do not confuse this acute chemical injury with chronic asthma management. The patient needs acute toxicological and critical care management, not adjustment of controller medications 2, 3.

Disposition Decision

• Discharge criteria: Significant improvement in symptoms and airflow after 3 doses of combined therapy, SpO2 >90%, able to speak in full sentences
• Admit if: Persistent severe symptoms after intensive treatment, signs of impending respiratory failure, significant hypoxemia, or development of pulmonary edema 2
• ICU/burn center transfer: Consider for severe exposures with mucosal burns, refractory hypoxemia, or need for intubation 2

Post-Exposure Follow-Up

Ammonia and other cleaning product exposures can cause new-onset occupational asthma or reactive airways dysfunction syndrome (RADS) with prolonged symptoms 3. Arrange pulmonary follow-up within 1-2 weeks to assess for persistent airway hyperreactivity.